Recursion Pharmaceuticals (RXRX) Enterprise Value (2020 - 2025)
Recursion Pharmaceuticals' Enterprise Value history spans 6 years, with the latest figure at -$747.9 million for Q4 2025.
- For Q4 2025, Enterprise Value fell 25.19% year-over-year to -$747.9 million; the TTM value through Dec 2025 reached -$747.9 million, down 25.19%, while the annual FY2025 figure was -$747.9 million, 25.19% down from the prior year.
- Enterprise Value reached -$747.9 million in Q4 2025 per RXRX's latest filing, down from -$663.0 million in the prior quarter.
- In the past five years, Enterprise Value ranged from a high of -$219.1 million in Q1 2021 to a low of -$747.9 million in Q4 2025.
- Average Enterprise Value over 5 years is -$490.5 million, with a median of -$489.8 million recorded in 2024.
- Peak YoY movement for Enterprise Value: plummeted 169.75% in 2022, then soared 36.87% in 2024.
- A 5-year view of Enterprise Value shows it stood at -$516.6 million in 2021, then decreased by 6.7% to -$551.2 million in 2022, then increased by 28.37% to -$394.8 million in 2023, then crashed by 51.32% to -$597.4 million in 2024, then fell by 25.19% to -$747.9 million in 2025.
- Per Business Quant, the three most recent readings for RXRX's Enterprise Value are -$747.9 million (Q4 2025), -$663.0 million (Q3 2025), and -$528.2 million (Q2 2025).